<p>Biodesix, Inc.（納斯達克代碼：BDSX - 獲取免費報告）在一月份的空頭頭寸顯著增長。截至 1 月 15 日，空頭頭寸總計為 483,591 股，比 12 月 31 日的 80,722 股增長了 499.1%。根據平均交易量 7,865,756 股，目前的空頭頭寸比率為 0.1 天。目前，公司 8.7% 的股票被賣空。</p>
<h2>Biodesix 價格表現</h2>
<p>BDSX 的股票在週三開盤價為 11.08 美元。該公司的 50 日移動平均線為 7.75 美元，200 日移動平均線為 7.73 美元。公司的債務與股本比率為 41.11，流動比率為 1.84，速動比率為 1.84。該公司的市值為 8815 萬美元，市盈率為-1.99，貝塔值為 0.60。Biodesix 的 52 周低點為 3.44 美元，52 周高點為 21.60 美元。</p>
<p>Biodesix（納斯達克代碼：BDSX - 獲取免費報告）最後一次公佈季度財報是在 11 月 3 日，報告顯示該季度每股收益為（1.16 美元），超出分析師一致預期的（1.60 美元）0.44 美元。該季度的營業收入為 2177 萬美元，而分析師預期為 2098 萬美元。Biodesix 的淨利潤率為-49.31%，股本回報率為-504.41%。股票分析師預測 Biodesix 在當前年度的每股收益為-0.35 美元。</p>
<h2>分析師評級調整</h2>
<p>多家券商最近對 BDSX 發表了評論。華爾街 Zen 在 11 月 8 日的研究報告中將 Biodesix 的評級從 “賣出” 上調至 “持有”。Weiss Ratings 在 12 月 22 日的研究報告中重申了對 Biodesix 的 “賣出（e+）” 評級。四位投資分析師給予該股票 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，共識目標價為 32.50 美元。</p>
<p><strong>查看我們對 BDSX 的最新分析</strong></p>
<h2>內部人士買賣情況</h2>
<p>在其他新聞中，董事 Jack W. Schuler 在 1 月 26 日的交易中購買了 20,000 股公司的股票。每股購買價格為 11.80 美元，總價值為 236,000.00 美元。購買後，該董事直接持有公司 1,563,210 股股票，價值為 18,445,878 美元。這筆交易代表其持股增加了 1.30%。該交易已在 SEC 的備案中披露，您可以通過此鏈接訪問。在過去一個季度，內部人士購買了 182,465 股公司股票，價值為 2,084,616 美元，並出售了 2,247 股，價值為 18,154 美元。公司內部人士持有 30.10% 的股票。</p>
<h2>機構投資者對 Biodesix 的看法</h2>
<p>多家機構投資者最近調整了對 BDSX 的持股。阿伯丁集團在第四季度購買了 Biodesix 的新頭寸，價值約為 1,784,000 美元。XTX Topco Ltd 在第二季度將其在 Biodesix 的持股增加了 99.4%。XTX Topco Ltd 現在擁有 205,647 股公司股票，價值 58,000 美元，此前在上個季度又購買了 102,494 股。甲骨文投資管理公司在第三季度收購了 Biodesix 的新頭寸，價值 113,000 美元。最後，千禧管理公司在第三季度購買了 Biodesix 的新頭寸，價值 113,000 美元。機構投資者持有公司 20.96% 的股票。</p>
<h2>關於 Biodesix</h2>
<p>（獲取免費報告）</p>
<p>Biodesix, Inc 是一家商業階段的分子診斷公司，總部位於科羅拉多州博爾德，開發和提供基於血液的檢測，以改善肺部疾病的診斷和管理，包括肺癌。該公司整合了先進的蛋白質組學和最近的基因組技術，提供旨在指導臨牀決策的非侵入性檢測解決方案。Biodesix 運營着一家 CLIA 認證和 CAP 認可的實驗室，能夠大規模處理患者樣本並保持嚴格的質量標準。</p>
<p>該公司的旗艦產品 VeriStrat®是一種蛋白質組學檢測，將非小細胞肺癌患者分層為更可能從特定療法中受益的組別。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票比 Biodesix 更好</li>
<li>美國的下一個權力舉動從地下開始</li>
<li>您的簽名缺失 - 請在為時已晚之前採取行動</li>
<li>緊急：特朗普剛剛引發了人工智能的最大幹擾</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>在週一上午 9:30 購買這隻股票！</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元在 Biodesix 嗎？</h2>
<p>在您考慮 Biodesix 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Biodesix 並不在名單上。</p>
<p>雖然 Biodesix 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

BDSX

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 ETF - SPDR

醫藥突破 ETF - ALPS

基因免疫&健康關懷 ETF - iShares

納斯達克生物科技指數 ETF - iShares Nasdaq

2 倍做多納斯達克生物技術 ETF - ProShares

基因改革 ETF - ARK

生物科技 ETF - VanEck Vectors

<p>Biodesix, Inc.（納斯達克代碼：BDSX）在短期空頭頭寸方面經歷了劇烈增長，1 月份上漲了 499.1%，總計達到 483,591 股。目前，該股票的空頭比例為 8.7%，根據平均交易量 7,865,756 股計算，覆蓋天數比率為 0.1 天。該公司的股票開盤價為 11.08 美元，市值為 8815 萬美元，市盈率為-1.99。最近的分析師評級顯示共識為 “適度買入”，目標價為 32.50 美元。內部人士近期也積極行動，購買了大量股份</p>

<p>Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) saw a significant growth in short interest in January. As of January 15th, there was short interest totaling 483,591 shares, a growth of 499.1% from the December 31st total of 80,722 shares. Based on an average trading volume of 7,865,756 shares, the short-interest ratio is presently 0.1 days. Currently, 8.7% of the company's stock are sold short. Currently, 8.7% of the company's stock are sold short. Based on an average trading volume of 7,865,756 shares, the short-interest ratio is presently 0.1 days.</p>
<div class="lb-trans"><p>Biodesix, Inc.（納斯達克代碼：BDSX - 獲取免費報告）在一月份的空頭頭寸顯著增長。截至 1 月 15 日，空頭頭寸總計為 483,591 股，比 12 月 31 日的 80,722 股增長了 499.1%。根據平均交易量 7,865,756 股，目前的空頭頭寸比率為 0.1 天。目前，公司 8.7% 的股票被賣空。</p>
</div><h2>Biodesix Price Performance</h2>
<div class="lb-trans"><h2>Biodesix 價格表現</h2>
</div><p>Shares of BDSX opened at $11.08 on Wednesday. The company's 50-day moving average is $7.75 and its 200-day moving average is $7.73. The company has a debt-to-equity ratio of 41.11, a current ratio of 1.84 and a quick ratio of 1.84. The firm has a market capitalization of $88.15 million, a PE ratio of -1.99 and a beta of 0.60. Biodesix has a fifty-two week low of $3.44 and a fifty-two week high of $21.60.</p>
<div class="lb-trans"><p>BDSX 的股票在週三開盤價為 11.08 美元。該公司的 50 日移動平均線為 7.75 美元，200 日移動平均線為 7.73 美元。公司的債務與股本比率為 41.11，流動比率為 1.84，速動比率為 1.84。該公司的市值為 8815 萬美元，市盈率為-1.99，貝塔值為 0.60。Biodesix 的 52 周低點為 3.44 美元，52 周高點為 21.60 美元。</p>
</div><p>Biodesix (NASDAQ:BDSX - Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($1.16) EPS for the quarter, beating analysts' consensus estimates of ($1.60) by $0.44. The business had revenue of $21.77 million for the quarter, compared to analyst estimates of $20.98 million. Biodesix had a negative net margin of 49.31% and a negative return on equity of 504.41%. Equities analysts forecast that Biodesix will post -0.35 EPS for the current year.</p>
<div class="lb-trans"><p>Biodesix（納斯達克代碼：BDSX - 獲取免費報告）最後一次公佈季度財報是在 11 月 3 日，報告顯示該季度每股收益為（1.16 美元），超出分析師一致預期的（1.60 美元）0.44 美元。該季度的營業收入為 2177 萬美元，而分析師預期為 2098 萬美元。Biodesix 的淨利潤率為-49.31%，股本回報率為-504.41%。股票分析師預測 Biodesix 在當前年度的每股收益為-0.35 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>A number of brokerages have recently commented on BDSX. Wall Street Zen raised shares of Biodesix from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 8th. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Biodesix in a research report on Monday, December 22nd. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $32.50.</p>
<div class="lb-trans"><p>多家券商最近對 BDSX 發表了評論。華爾街 Zen 在 11 月 8 日的研究報告中將 Biodesix 的評級從 “賣出” 上調至 “持有”。Weiss Ratings 在 12 月 22 日的研究報告中重申了對 Biodesix 的 “賣出（e+）” 評級。四位投資分析師給予該股票 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，共識目標價為 32.50 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on BDSX</strong></p>
<div class="lb-trans"><p><strong>查看我們對 BDSX 的最新分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣情況</h2>
</div><p>In other news, Director Jack W. Schuler purchased 20,000 shares of the company's stock in a transaction on Monday, January 26th. The shares were purchased at an average price of $11.80 per share, with a total value of $236,000.00. Following the purchase, the director directly owned 1,563,210 shares of the company's stock, valued at $18,445,878. This trade represents a 1.30% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders have acquired 182,465 shares of company stock valued at $2,084,616 and have sold 2,247 shares valued at $18,154. Corporate insiders own 30.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，董事 Jack W. Schuler 在 1 月 26 日的交易中購買了 20,000 股公司的股票。每股購買價格為 11.80 美元，總價值為 236,000.00 美元。購買後，該董事直接持有公司 1,563,210 股股票，價值為 18,445,878 美元。這筆交易代表其持股增加了 1.30%。該交易已在 SEC 的備案中披露，您可以通過此鏈接訪問。在過去一個季度，內部人士購買了 182,465 股公司股票，價值為 2,084,616 美元，並出售了 2,247 股，價值為 18,154 美元。公司內部人士持有 30.10% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Biodesix</h2>
<div class="lb-trans"><h2>機構投資者對 Biodesix 的看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of BDSX. Aberdeen Group plc bought a new position in shares of Biodesix during the fourth quarter worth approximately $1,784,000. XTX Topco Ltd grew its stake in shares of Biodesix by 99.4% during the second quarter. XTX Topco Ltd now owns 205,647 shares of the company's stock worth $58,000 after buying an additional 102,494 shares during the last quarter. Oracle Investment Management Inc. acquired a new position in shares of Biodesix during the third quarter worth $113,000. Finally, Millennium Management LLC bought a new position in shares of Biodesix in the 3rd quarter valued at $113,000. Institutional investors own 20.96% of the company's stock.</p>
<div class="lb-trans"><p>多家機構投資者最近調整了對 BDSX 的持股。阿伯丁集團在第四季度購買了 Biodesix 的新頭寸，價值約為 1,784,000 美元。XTX Topco Ltd 在第二季度將其在 Biodesix 的持股增加了 99.4%。XTX Topco Ltd 現在擁有 205,647 股公司股票，價值 58,000 美元，此前在上個季度又購買了 102,494 股。甲骨文投資管理公司在第三季度收購了 Biodesix 的新頭寸，價值 113,000 美元。最後，千禧管理公司在第三季度購買了 Biodesix 的新頭寸，價值 113,000 美元。機構投資者持有公司 20.96% 的股票。</p>
</div><h2>About Biodesix</h2>
<div class="lb-trans"><h2>關於 Biodesix</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.</p>
<div class="lb-trans"><p>Biodesix, Inc 是一家商業階段的分子診斷公司，總部位於科羅拉多州博爾德，開發和提供基於血液的檢測，以改善肺部疾病的診斷和管理，包括肺癌。該公司整合了先進的蛋白質組學和最近的基因組技術，提供旨在指導臨牀決策的非侵入性檢測解決方案。Biodesix 運營着一家 CLIA 認證和 CAP 認可的實驗室，能夠大規模處理患者樣本並保持嚴格的質量標準。</p>
</div><p>The company's flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.</p>
<div class="lb-trans"><p>該公司的旗艦產品 VeriStrat®是一種蛋白質組學檢測，將非小細胞肺癌患者分層為更可能從特定療法中受益的組別。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Biodesix</li>
<li>America's Next Power Move Starts Underground</li>
<li>Your Signature Is Missing – Act Before It’s Too Late</li>
<li>URGENT: Trump Just Triggered AI’s Biggest Disruption Yet</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>Buy This Stock at 9:30 AM on MONDAY!</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Biodesix 更好</li>
<li>美國的下一個權力舉動從地下開始</li>
<li>您的簽名缺失 - 請在為時已晚之前採取行動</li>
<li>緊急：特朗普剛剛引發了人工智能的最大幹擾</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>在週一上午 9:30 購買這隻股票！</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Biodesix Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Biodesix 嗎？</h2>
</div><p>Before you consider Biodesix, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Biodesix 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biodesix wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Biodesix 並不在名單上。</p>
</div><p>While Biodesix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Biodesix 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Increases By 499.1%

Market Beat

Biodesix

Biodesix 公司（NASDAQ 代碼：BDSX）的空頭頭寸增加了 499.1%